Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sunshine Biopharma Inc. - Common stock (NQ:SBFM)

1.300 +0.030 (+2.36%)
Streaming Delayed Price Updated: 12:28 PM EDT, May 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sunshine Biopharma Inc. - Common stock

< Previous 1 2 Next >
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market
Via ACCESS Newswire
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion
Via ACCESS Newswire
BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Secures $2.46M in Registered Direct
Via Investor Brand Network
Exposures COVID-19
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering
Via ACCESS Newswire
Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry
Via ACCESSWIRE
Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023
Via ACCESSWIRE
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
Via ACCESS Newswire
Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer
Via ACCESS Newswire
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
Via ACCESS Newswire
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada
Via ACCESS Newswire
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
Via ACCESS Newswire
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
Via ACCESS Newswire
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
Via ACCESSWIRE
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus
Via ACCESSWIRE
Sunshine Biopharma Launches a New Generic Prescription Drug
Via ACCESSWIRE
Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma
Via ACCESSWIRE
Sunshine Biopharma Launches a New Generic Prescription Drug
Via ACCESSWIRE
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%
Via ACCESSWIRE
Sunshine Biopharma Launches Two New Generic Prescription Drugs
Via ACCESSWIRE
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
From FN Media Group LLC
Via GlobeNewswire
SUNSHINE BIOPHARMA ANNOUNCES PUBLICATION OF SIGNIFICANT CORONAVIRUS RESEARCH RESULTS IN THE JOURNAL OF MEDICINAL CHEMISTRY
Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18% Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both... 
Via FinancialNewsMedia
Exposures COVID-19
Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada
Via ACCESSWIRE
Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%
Via ACCESSWIRE
Sunshine Biopharma Announces Reverse Stock Split
Via ACCESSWIRE
Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%
Via ACCESSWIRE
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)
Via ACCESSWIRE
Sunshine Biopharma Announces Reverse Stock Split
Via ACCESSWIRE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.